La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Pharming a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Pharming..

Pharming (NASDAQ:PHAR) Azioni, Catena delle Opzioni

PHARMING GROUP NV - ADR

Pharming

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming Group

PHARMATHER HLDGS LTD by PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd

PHARMAGREEN BIOTECH INC by Pharmagreen Biotech Inc.

Pharmagreen Biotech Inc

Pharvaris NV

PharmaCyte Biotech Inc

Pharmadrug Inc

PHARMALA BIOTECH HLDG INC by PharmAla Biotech Holdings Inc.

Pharmala Biotech Holdings Inc

PharmaCielo Ltd

Pharma Mar SA

PHARMARON BEIJING U/ADR by PHARMARON BEIJING CO LTD.

PHARNEXT by Pharnext

PHarol SGPS SA

PharmChem Inc

PHARMA FOODS INTL CO by Pharma Foods International Co., Ltd.

Pharma Foods International Co Ltd

PHARM-BIO SERV INC by Pharma-Bio Serv, Inc.

Pharma-Bio Serv Inc

PHARMACOM BIOVET INC by PharmaCom BioVet, Inc.

PharmaCom BioVet Inc

PHARMAROTH LABS INC by PharmaRoth Labs, Inc.

PharmaRoth Labs Inc

Pharmagen Inc

PHARMARON BEIJING CO LTD by PHARMARON BEIJING CO LTD.

Pharmaron Beijing Co Ltd

PHARMING GROUP NV ORD by Pharming Group NV

Pharnext SA

Pharos Energy PLC

Earnings

News

Management

Press Releases

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Pharming Group to report second quarter and  first half 2025 financial results and provide business update on July 31

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Pharming Group to participate in August investor conference

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

Pharming Group promoted to the Euronext AMX® index

General

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

Pharming Group provides update on previously announced G&A expense reduction plan

PHAR

AnaptysBio

Ardelyx

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

Bicara Therapeutics

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Immatics

Inventiva S.A. - American Depository Shares

Inventiva

Kura Oncology

MiMedx Group

Nanobiotix

Oruka Therapeutics

Precigen

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prime Medicine

Relay Therapeutics

Sana Biotechnology

ARS Pharmaceuticals

Spyre Therapeutics

Tourmaline Bio

Taysha Gene Therapies, Inc. - Common Stock

Comments

Pharming

Pharming (PHAR) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO